Peiseler Moritz, Tacke Frank
Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Cancers (Basel). 2021 Feb 10;13(4):730. doi: 10.3390/cancers13040730.
Nonalcoholic fatty liver disease (NAFLD) is a rising chronic liver disease and comprises a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to end-stage cirrhosis and risk of hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is multifactorial, but inflammation is considered the key element of disease progression. The liver harbors an abundance of resident immune cells, that in concert with recruited immune cells, orchestrate steatohepatitis. While inflammatory processes drive fibrosis and disease progression in NASH, fueling the ground for HCC development, immunity also exerts antitumor activities. Furthermore, immunotherapy is a promising new treatment of HCC, warranting a more detailed understanding of inflammatory mechanisms underlying the progression of NASH and transition to HCC. Novel methodologies such as single-cell sequencing, genetic fate mapping, and intravital microscopy have unraveled complex mechanisms behind immune-mediated liver injury. In this review, we highlight some of the emerging paradigms, including macrophage heterogeneity, contributions of nonclassical immune cells, the role of the adaptive immune system, interorgan crosstalk with adipose tissue and gut microbiota. Furthermore, we summarize recent advances in preclinical and clinical studies aimed at modulating the inflammatory cascade and discuss how these novel therapeutic avenues may help in preventing or combating NAFLD-associated HCC.
非酒精性脂肪性肝病(NAFLD)是一种日益常见的慢性肝病,其范围涵盖从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH),再到终末期肝硬化以及肝细胞癌(HCC)风险。NAFLD的发病机制是多因素的,但炎症被认为是疾病进展的关键因素。肝脏中存在大量驻留免疫细胞,这些细胞与募集来的免疫细胞协同作用,共同引发脂肪性肝炎。虽然炎症过程会推动NASH中的纤维化和疾病进展,为HCC的发展埋下隐患,但免疫也具有抗肿瘤活性。此外,免疫疗法是一种有前景的HCC新疗法,这就需要更详细地了解NASH进展及向HCC转变背后的炎症机制。诸如单细胞测序、基因命运图谱和活体显微镜检查等新方法已经揭示了免疫介导的肝损伤背后的复杂机制。在本综述中,我们重点介绍一些新出现的模式,包括巨噬细胞异质性、非经典免疫细胞的作用、适应性免疫系统的作用、与脂肪组织和肠道微生物群的器官间相互作用。此外,我们总结了旨在调节炎症级联反应的临床前和临床研究的最新进展,并讨论这些新的治疗途径如何有助于预防或对抗与NAFLD相关的HCC。